Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of pictilisib alone or with carboplatin/paclitaxel + bevacizumab in solid tumors and non-squamous NSCLC
jRCT2080222116Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pictilisib in Nonhematologic neoplasms and Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of pictilisib alone and in combination.
02
Drugs
pictilisib
03
Conditions
Nonhematologic neoplasmsNon-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2080222116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222116.